Baidu
map

Nat Commun:乳腺癌药物或可抵御耐药性细菌的感染

2015-10-16 佚名 生物谷

图片来源:medicalxpress.com 刊登在国际杂志Nature Communications上的一项研究论文中,来自加利福尼亚大学等处的研究人员通过研究发现,乳腺癌药物他莫昔芬可以促进白血球细胞迅速增加,并且在实验室研究中可以对细菌快速产生反应,并且杀灭细菌,在小鼠机体中进行的他莫昔芬疗法可以有效增强小鼠机体清除耐药性MRSA的效率,并且有效降低小鼠的死亡率。 他莫昔芬可以靶向作

图片来源:medicalxpress.com

刊登在国际杂志Nature Communications上的一项研究论文中,来自加利福尼亚大学等处的研究人员通过研究发现,乳腺癌药物他莫昔芬可以促进白血球细胞迅速增加,并且在实验室研究中可以对细菌快速产生反应,并且杀灭细菌,在小鼠机体中进行的他莫昔芬疗法可以有效增强小鼠机体清除耐药性MRSA的效率,并且有效降低小鼠的死亡率。

他莫昔芬可以靶向作用雌激素受体,使其有效杀灭分子异常的乳腺癌细胞,但有些研究证据表明,他莫昔芬或许还具有其它有效的细胞效应,比如,他莫昔芬可以影响细胞产生脂肪分子的途径,比如鞘脂类等,而其并不依赖于雌激素受体。鞘脂,尤其是其中一种名为神经酰胺的分子在调节中性白细胞上扮演着重要角色。

Ross Corriden博士表示,他莫昔芬对神经酰胺类的效应可以帮助研究者们证实,当其给予病人治疗时,他莫昔芬就可以影响中性白细胞的行为,为了检测这一理论,研究人员利用他莫昔芬来孵育人类中性白细胞,相比较未处理的中性白细胞而言,研究者发现,他莫昔芬处理过的中性白细胞可以更好地向前移动及对细菌发生吞噬作用;同时他莫昔芬处理过的中性白细胞还可以产生三倍水平的中性粒细胞胞外诱捕网(NETs),其可以帮助中性白细胞来诱捕并杀灭病原体,利用靶向作用雌激素受体的的分子来作用中性白细胞并没有任何效应,这就表明,他莫昔芬可以以一种和雌激素受体不相关的途径来增强NET的产生,深入研究发现,他莫昔芬可以增强中性白细胞中的神经酰胺的水平。

随后研究人员在小鼠模型中检测了他莫昔芬增强免疫力的效应,利用他莫昔芬或对照分子治疗一小时后,研究者利用MRSA感染小鼠,随后再利用他莫昔芬或对照治疗小鼠,在感染8小时候连续对小鼠监测5天观察其表现。结果显示,他莫昔芬可以明显保护小鼠免于感染的发生,有大约35%的他莫昔芬治疗的小鼠都存活了5天。

本文研究中,研究者发现,他莫昔芬可以帮助有效抵御MRSA的感染,而结果因不同病原体而异,当感染不存在时,过多NETs的产生会对机体是有害的,有很多研究都发现过量NETs的产生和炎性疾病直接相关,比如脉管炎和支气管哮喘等。

原文出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1072109, encodeId=4a9310e21091e, content=已阅,受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Sat Nov 20 10:27:33 CST 2021, time=2021-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086832, encodeId=36a6208683234, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Mon Jan 04 10:07:00 CST 2016, time=2016-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880842, encodeId=77bd188084207, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Nov 13 12:07:00 CST 2015, time=2015-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39563, encodeId=63b33956366, content=赞一个~, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/26/5e1df344d663496bdfd43c465d409e2c.jpg, createdBy=bce679058, createdName=sunlong28, createdTime=Mon Oct 19 12:20:00 CST 2015, time=2015-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39564, encodeId=c7453956494, content=感谢分享~, beContent=null, objectType=article, channel=null, level=null, likeNumber=172, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/26/5e1df344d663496bdfd43c465d409e2c.jpg, createdBy=bce679058, createdName=sunlong28, createdTime=Mon Oct 19 12:20:00 CST 2015, time=2015-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39565, encodeId=af6439565b1, content=谢谢~, beContent=null, objectType=article, channel=null, level=null, likeNumber=181, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/26/5e1df344d663496bdfd43c465d409e2c.jpg, createdBy=bce679058, createdName=sunlong28, createdTime=Mon Oct 19 12:20:00 CST 2015, time=2015-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39566, encodeId=a0fe39566d9, content=为了积分我也是拼了~, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/26/5e1df344d663496bdfd43c465d409e2c.jpg, createdBy=bce679058, createdName=sunlong28, createdTime=Mon Oct 19 12:20:00 CST 2015, time=2015-10-19, status=1, ipAttribution=)]
    2021-11-20 湘雅科教

    已阅,受益匪浅。

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1072109, encodeId=4a9310e21091e, content=已阅,受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Sat Nov 20 10:27:33 CST 2021, time=2021-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086832, encodeId=36a6208683234, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Mon Jan 04 10:07:00 CST 2016, time=2016-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880842, encodeId=77bd188084207, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Nov 13 12:07:00 CST 2015, time=2015-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39563, encodeId=63b33956366, content=赞一个~, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/26/5e1df344d663496bdfd43c465d409e2c.jpg, createdBy=bce679058, createdName=sunlong28, createdTime=Mon Oct 19 12:20:00 CST 2015, time=2015-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39564, encodeId=c7453956494, content=感谢分享~, beContent=null, objectType=article, channel=null, level=null, likeNumber=172, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/26/5e1df344d663496bdfd43c465d409e2c.jpg, createdBy=bce679058, createdName=sunlong28, createdTime=Mon Oct 19 12:20:00 CST 2015, time=2015-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39565, encodeId=af6439565b1, content=谢谢~, beContent=null, objectType=article, channel=null, level=null, likeNumber=181, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/26/5e1df344d663496bdfd43c465d409e2c.jpg, createdBy=bce679058, createdName=sunlong28, createdTime=Mon Oct 19 12:20:00 CST 2015, time=2015-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39566, encodeId=a0fe39566d9, content=为了积分我也是拼了~, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/26/5e1df344d663496bdfd43c465d409e2c.jpg, createdBy=bce679058, createdName=sunlong28, createdTime=Mon Oct 19 12:20:00 CST 2015, time=2015-10-19, status=1, ipAttribution=)]
    2016-01-04 liuli5079
  3. [GetPortalCommentsPageByObjectIdResponse(id=1072109, encodeId=4a9310e21091e, content=已阅,受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Sat Nov 20 10:27:33 CST 2021, time=2021-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086832, encodeId=36a6208683234, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Mon Jan 04 10:07:00 CST 2016, time=2016-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880842, encodeId=77bd188084207, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Nov 13 12:07:00 CST 2015, time=2015-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39563, encodeId=63b33956366, content=赞一个~, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/26/5e1df344d663496bdfd43c465d409e2c.jpg, createdBy=bce679058, createdName=sunlong28, createdTime=Mon Oct 19 12:20:00 CST 2015, time=2015-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39564, encodeId=c7453956494, content=感谢分享~, beContent=null, objectType=article, channel=null, level=null, likeNumber=172, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/26/5e1df344d663496bdfd43c465d409e2c.jpg, createdBy=bce679058, createdName=sunlong28, createdTime=Mon Oct 19 12:20:00 CST 2015, time=2015-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39565, encodeId=af6439565b1, content=谢谢~, beContent=null, objectType=article, channel=null, level=null, likeNumber=181, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/26/5e1df344d663496bdfd43c465d409e2c.jpg, createdBy=bce679058, createdName=sunlong28, createdTime=Mon Oct 19 12:20:00 CST 2015, time=2015-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39566, encodeId=a0fe39566d9, content=为了积分我也是拼了~, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/26/5e1df344d663496bdfd43c465d409e2c.jpg, createdBy=bce679058, createdName=sunlong28, createdTime=Mon Oct 19 12:20:00 CST 2015, time=2015-10-19, status=1, ipAttribution=)]
    2015-11-13 liye789132251
  4. [GetPortalCommentsPageByObjectIdResponse(id=1072109, encodeId=4a9310e21091e, content=已阅,受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Sat Nov 20 10:27:33 CST 2021, time=2021-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086832, encodeId=36a6208683234, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Mon Jan 04 10:07:00 CST 2016, time=2016-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880842, encodeId=77bd188084207, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Nov 13 12:07:00 CST 2015, time=2015-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39563, encodeId=63b33956366, content=赞一个~, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/26/5e1df344d663496bdfd43c465d409e2c.jpg, createdBy=bce679058, createdName=sunlong28, createdTime=Mon Oct 19 12:20:00 CST 2015, time=2015-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39564, encodeId=c7453956494, content=感谢分享~, beContent=null, objectType=article, channel=null, level=null, likeNumber=172, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/26/5e1df344d663496bdfd43c465d409e2c.jpg, createdBy=bce679058, createdName=sunlong28, createdTime=Mon Oct 19 12:20:00 CST 2015, time=2015-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39565, encodeId=af6439565b1, content=谢谢~, beContent=null, objectType=article, channel=null, level=null, likeNumber=181, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/26/5e1df344d663496bdfd43c465d409e2c.jpg, createdBy=bce679058, createdName=sunlong28, createdTime=Mon Oct 19 12:20:00 CST 2015, time=2015-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39566, encodeId=a0fe39566d9, content=为了积分我也是拼了~, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/26/5e1df344d663496bdfd43c465d409e2c.jpg, createdBy=bce679058, createdName=sunlong28, createdTime=Mon Oct 19 12:20:00 CST 2015, time=2015-10-19, status=1, ipAttribution=)]
    2015-10-19 sunlong28

    赞一个~

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1072109, encodeId=4a9310e21091e, content=已阅,受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Sat Nov 20 10:27:33 CST 2021, time=2021-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086832, encodeId=36a6208683234, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Mon Jan 04 10:07:00 CST 2016, time=2016-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880842, encodeId=77bd188084207, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Nov 13 12:07:00 CST 2015, time=2015-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39563, encodeId=63b33956366, content=赞一个~, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/26/5e1df344d663496bdfd43c465d409e2c.jpg, createdBy=bce679058, createdName=sunlong28, createdTime=Mon Oct 19 12:20:00 CST 2015, time=2015-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39564, encodeId=c7453956494, content=感谢分享~, beContent=null, objectType=article, channel=null, level=null, likeNumber=172, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/26/5e1df344d663496bdfd43c465d409e2c.jpg, createdBy=bce679058, createdName=sunlong28, createdTime=Mon Oct 19 12:20:00 CST 2015, time=2015-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39565, encodeId=af6439565b1, content=谢谢~, beContent=null, objectType=article, channel=null, level=null, likeNumber=181, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/26/5e1df344d663496bdfd43c465d409e2c.jpg, createdBy=bce679058, createdName=sunlong28, createdTime=Mon Oct 19 12:20:00 CST 2015, time=2015-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39566, encodeId=a0fe39566d9, content=为了积分我也是拼了~, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/26/5e1df344d663496bdfd43c465d409e2c.jpg, createdBy=bce679058, createdName=sunlong28, createdTime=Mon Oct 19 12:20:00 CST 2015, time=2015-10-19, status=1, ipAttribution=)]
    2015-10-19 sunlong28

    感谢分享~

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1072109, encodeId=4a9310e21091e, content=已阅,受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Sat Nov 20 10:27:33 CST 2021, time=2021-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086832, encodeId=36a6208683234, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Mon Jan 04 10:07:00 CST 2016, time=2016-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880842, encodeId=77bd188084207, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Nov 13 12:07:00 CST 2015, time=2015-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39563, encodeId=63b33956366, content=赞一个~, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/26/5e1df344d663496bdfd43c465d409e2c.jpg, createdBy=bce679058, createdName=sunlong28, createdTime=Mon Oct 19 12:20:00 CST 2015, time=2015-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39564, encodeId=c7453956494, content=感谢分享~, beContent=null, objectType=article, channel=null, level=null, likeNumber=172, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/26/5e1df344d663496bdfd43c465d409e2c.jpg, createdBy=bce679058, createdName=sunlong28, createdTime=Mon Oct 19 12:20:00 CST 2015, time=2015-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39565, encodeId=af6439565b1, content=谢谢~, beContent=null, objectType=article, channel=null, level=null, likeNumber=181, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/26/5e1df344d663496bdfd43c465d409e2c.jpg, createdBy=bce679058, createdName=sunlong28, createdTime=Mon Oct 19 12:20:00 CST 2015, time=2015-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39566, encodeId=a0fe39566d9, content=为了积分我也是拼了~, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/26/5e1df344d663496bdfd43c465d409e2c.jpg, createdBy=bce679058, createdName=sunlong28, createdTime=Mon Oct 19 12:20:00 CST 2015, time=2015-10-19, status=1, ipAttribution=)]
    2015-10-19 sunlong28

    谢谢~

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1072109, encodeId=4a9310e21091e, content=已阅,受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Sat Nov 20 10:27:33 CST 2021, time=2021-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086832, encodeId=36a6208683234, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Mon Jan 04 10:07:00 CST 2016, time=2016-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880842, encodeId=77bd188084207, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Nov 13 12:07:00 CST 2015, time=2015-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39563, encodeId=63b33956366, content=赞一个~, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/26/5e1df344d663496bdfd43c465d409e2c.jpg, createdBy=bce679058, createdName=sunlong28, createdTime=Mon Oct 19 12:20:00 CST 2015, time=2015-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39564, encodeId=c7453956494, content=感谢分享~, beContent=null, objectType=article, channel=null, level=null, likeNumber=172, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/26/5e1df344d663496bdfd43c465d409e2c.jpg, createdBy=bce679058, createdName=sunlong28, createdTime=Mon Oct 19 12:20:00 CST 2015, time=2015-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39565, encodeId=af6439565b1, content=谢谢~, beContent=null, objectType=article, channel=null, level=null, likeNumber=181, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/26/5e1df344d663496bdfd43c465d409e2c.jpg, createdBy=bce679058, createdName=sunlong28, createdTime=Mon Oct 19 12:20:00 CST 2015, time=2015-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39566, encodeId=a0fe39566d9, content=为了积分我也是拼了~, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/26/5e1df344d663496bdfd43c465d409e2c.jpg, createdBy=bce679058, createdName=sunlong28, createdTime=Mon Oct 19 12:20:00 CST 2015, time=2015-10-19, status=1, ipAttribution=)]
    2015-10-19 sunlong28

    为了积分我也是拼了~

    0

相关资讯

NEJM:依西美坦或为年轻乳腺癌患者的新选择

对于已接受卵巢功能抑制治疗的激素受体阳性的早期乳腺癌">乳腺癌患者来言,依西美坦辅助化疗较他莫昔芬比或更能提高预后。 激素受体阳性的早期乳腺癌绝经前女性都会接受至少5-10年他莫昔芬的治疗。但是卵巢功能抑制(OFS)治疗联合他莫昔芬或芳香酶抑制剂(AI)治疗,二者的复发率、生存率孰优孰劣尚不得知。 研究者们开展了2项随机的Ⅲ期临床试验(TEXT试验 和 SOFT试验),对比卵巢OFS联合

Clin Cancer Res:喝咖啡能抑制乳腺癌生长

大量的研究表明,喝咖啡有助于预防乳腺癌。Lund大学领导的一项最新研究证实,对于被诊断出患有乳腺癌并且应用他莫昔芬进行治疗的女性,喝咖啡可以抑制肿瘤的生长,减少复发的风险。该项研究结果发表在最新一期Clinical Cancer Research杂志上。这项研究是由英国Lund大学的Skåne大学医院的研究人员为期两年的随访研究数据收集并统计分析而来。研究人员对瑞典1090名诊断为原发侵袭性乳腺癌

N Engl J Med:辅助卵巢抑制治疗在绝经前乳腺癌的应用研究

背景抑制卵巢雌激素分泌能够减少雌激素受体阳性的绝经前女性的早期乳腺癌的复发率,但是它的作用在加入泰莫西芬(三苯氧胺,雌激素拮抗药)后是不确定的。方法随机地分配3066个绝经前女性,根据优先接受和未接受化疗分组,接受5年的泰莫西芬治疗,其中泰莫西芬联合卵巢抑制,或者依西美坦联合卵巢抑制。主要分析验证泰莫西芬联合卵巢抑制以提升无病生存率的假设,与单纯使用泰莫西芬进行比较。在总体分析中,46.7%的病人

NEJM:未绝经乳腺癌患者的内分泌治疗

对于绝经前早期乳癌女性患者,若病灶免疫组化结果提示雌激素受体阳性或孕激素受体阳性,临床上通常会行内分泌治疗——使用药物抑制卵巢功能,减少雌激素生产,从而减少乳癌复发,但是目前对于该类患者使用添加了他莫昔芬的抑制卵巢雌激素生成疗法的疗效并不明确。因此Prudence A等人进行了一项试验,以评估对进行了完整化疗后未绝经患者以及单独使用他莫昔芬的未绝经患者,行辅助内分泌治疗是否合适。研究的初始数据分析

J Natl Cancer Inst:他莫昔芬治疗乳腺癌预后得以改善

先前研究表明,他莫昔芬治疗后乳腺癌患者乳腺密度降低生存状况得以改善,但这种治疗排除了绝经前女性。因此,我们评估了年龄为32-87岁的患者使用他莫昔芬治疗后乳腺密度的改变和乳腺癌死亡数。 本病例对照研究纳入了来自1990-2008年俄勒冈州波特兰的凯撒医疗机构的349位ER阳性乳腺癌患者,其中97名死于乳腺癌(病例组),252位没有乳腺癌相关死亡(对照组),按照年龄和诊断阶段将两组患者进行分配。测

Lancet:芳香化酶抑制剂 vs 他莫昔芬治疗早期乳腺癌

使用芳香化酶抑制剂或他莫昔芬作为早期乳腺癌的内分泌治疗的最佳方式仍存在不确定性。    研究人员对31920例绝经后患有雌激素受体阳性的早期乳腺癌的女性患者进行了个人数据的荟萃分析,该随机试验包括:第1组为芳香酶抑制剂 vs 他莫昔芬分别进行5年治疗;第2组为5年的芳香化酶抑制剂 vs 2〜3年的他莫昔芬然后应用芳香化酶抑制剂治疗到第5年;第3组为2—3年的他莫昔芬然

Baidu
map
Baidu
map
Baidu
map